Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 7, 2014, Pages 1033-1039

  Wang, Xiying ^a,b   Sawada, Tomoko ^a   Kakinoki, Masashi ^a   Miyake, Taichiro ^a   Kawamura, Hajime ^a   Saishin, Yoshitsugu ^a   Liu, Ping ^b   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Aqueous humor; Bimonthly intravitreal injection; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TISSUE DISTRIBUTION; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84904357863     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2505-2     Document Type: Article

References (34)

1. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92:10457-10461
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855-868
3. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122:393-403 (Pubitemid 26300056)
4. Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929-1934 (Pubitemid 26324159)
5. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154-162 (Pubitemid 27092496)
6. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338-346 (Pubitemid 34250056)
7. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1-29 (Pubitemid 36207453)
8. Klaver CC,Wolfs RC, Vingerling JR, Hofman A, de Jong PT (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116:653-658 (Pubitemid 28414581)
9. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900-1901
10. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group (2004) Prevalence of age-relatedmacular degeneration in the United States. Arch Ophthalmol 122:564-572 (Pubitemid 38456293)
11. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP,Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844-851 (Pubitemid 39573742)
12. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456-462 (Pubitemid 43265948)
13. Jonas JB, Neumaier M (2007) Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 39:139-142 (Pubitemid 46975978)
14. Ahn JK, Moon HJ (2009) Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative agerelated macular degeneration. Am J Ophthalmol 148:718-724
15. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U (2009) Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116:2393-2399
16. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M (2010) Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Retina 30:1034-1038
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431 (Pubitemid 44511557)
18. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444 (Pubitemid 44511558)
19. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt- Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2-13
20. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
21. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration PIER study year 2. Am J Ophthalmol 150:315-324
22. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831-839
23. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: AVEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398 (Pubitemid 34920936)
24. US Food and Drug Administration (2011) FDA labeling information - Eylea http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125387lbl.pdf. Accessed Nov 2011
25. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537-2548
26. Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:119-134
27. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S (2005) Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243:3-8
28. Bakri SJ, Shyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182 (Pubitemid 350181137)
29. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab (rhufabv2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733 (Pubitemid 40270359)
30. Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682-686
31. Lucentis (ranibizumab injection). Highlights of prescribing information. Available at: http://www.gene.com/gene/products/information/pdf/lucentis- prescribing.pdf. Accessed April 15, 2011.
32. Hoerster R, Muether PS, Hermann MM, Koch K, Kirchhof B, Fauser S (2011) Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. Br J Ophthalmol 95:1424-1426
33. Muether PS, HermannMM, Viebahn U, Kirchhof B, Fauser S (2012) Vascular endothelial growth factor in patients with exudative agerelated macular degeneration treated with ranibizumab. Ophthalmology 119:2082-2086
34. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM, CLEAR-IT 2 Investigators (2011) CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118:1098-1106